10x Genomics, Inc. reported products and services revenue of $150.2 million for the three months ended September 30, 2026, up 1%, while gross margin rose to 75%. It agreed to acquire Proteintech Genomics, Inc. for $6.1 million.
TXG · 10x Genomics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 34%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 6
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
10x Genomics reported third-quarter revenue of $150.7 million, up 1%, raised its 2026 revenue outlook to $625 million to $635 million and expects approximately 50 ATERRA instruments by year-end, up from approximately 40.
10x Genomics, Inc. reported third-quarter 2026 revenue of $150.7 million, up 1% year over year, and net loss of $19.4 million; it raised full-year revenue guidance to $625 million to $635 million.
10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors effective October 28, 2026. Gilliam was also named Audit Committee Chair on October 30, 2026, with a $25,000 annual retainer.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. 10x raised full-year revenue guidance and increased its ATERRA shipment outlook, while gross margin improved, losses narrowed, spatial consumables grew 16%, and ATERRA demand remained strong. Instrument revenue fell sharply, near-term and 2027 gross margins are expected to be lower, and production and installation capacity are expected to constrain ATERRA shipments into next year.
- + Full-year 2026 revenue guidance was raised to $625 million-$635 million from $610 million-$630 million.
- + The expected ATERRA shipment count increased to approximately 50 instruments by year-end from approximately 40. new
- + Third-quarter gross margin increased to 75% from 67% in the prior-year period. new
- + Operating loss and net loss narrowed from the prior-year period. new
- − Total instrument revenue declined 43%, with chromium instrument revenue down 23% and spatial instrument revenue down 57%.
- − Fourth-quarter gross margin is expected to be in the low-to-mid 60s as ATERRA shipments ramp. new
- − Gross margin is expected to be lower in 2027 because it will be an instrument-heavy year and consumables will ramp during the year. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross margin | 75% | the third quarter of 2026 | — |
| Total consumables revenue | 134.33M | Three Months Ended September 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TXG
this stock
10x Genomics, Inc.
|
$6.81B | +217.6% | +68.1% | — | 9.5% |
|
ABT
Abbott Laboratories
|
$178.39B | -17.8% | +5.7% | 38.4 | 1.1% |
|
MDT
Medtronic plc
|
$127.84B | +4.0% | +8.4% | 24.6 | 1.8% |
|
SYK
Stryker Corp
|
$118.01B | -11.8% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$60.85B | -56.0% | +12.5% | 17.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 6, 2026
- This year
- 14
10x Genomics, Inc. reported products and services revenue of $150.2 million for the three months ended September 30, 2026, up 1%, while gross margin rose to 75%. It agreed to acquire Proteintech Genomics, Inc. for $6.1 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TXG | -11.0% | -27.6% | +68.7% | -26.1% | +217.6% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -2.4% | -18.4% | +77.9% | -17.4% | +216.4% |